NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW)

CUSIP: N62509117

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class
Equity / *W EXP 99/99/999
Total 13F shares
1,569,132
Share change
-52,638
Total reported value
$4,909,805
Price per share
$3.13
Number of holders
17
Value change
-$72,143
Number of buys
1
Number of sells
4

Quarterly Holders Quick Answers

What is CUSIP N62509117?
CUSIP N62509117 identifies NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q4 2023

As of 31 Dec 2023, NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) was held by 17 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,569,132 shares. The largest 10 holders included Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., Ensign Peak Advisors, Inc, Affinity Asset Advisors, LLC, Bain Capital Life Sciences Investors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ADAR1 Capital Management, LLC, Westchester Capital Management, LLC, HRT FINANCIAL LP, and Walleye Capital LLC. This page lists 17 institutional shareholders reporting positions in this security for the Q4 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.